Vutrisiran shows promise for Long-Term control of rare heart condition

NCT ID NCT06679946

ENROLLING_BY_INVITATION Disease control Sponsor: Alnylam Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is for people with a rare heart condition called ATTR amyloidosis with cardiomyopathy, where abnormal protein builds up in the heart. It tests the long-term safety and effectiveness of a drug called vutrisiran, given as an injection every three months. About 700 adults who were already in earlier studies of vutrisiran or a similar drug (patisiran) will take part. The goal is to see if the drug remains safe and helps control the disease over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

vutrisiran (a drug given as an injection every 3 months)

What this could lead to

If successful, this study could confirm that vutrisiran is a safe and effective long-term treatment for people with ATTR amyloidosis with cardiomyopathy, helping to manage the disease and improve quality of life.

What could go wrong

This is an extension study, not a new treatment test. It is open-label (everyone knows they get the drug), so results may be less reliable. Side effects are possible, and the drug may not work for everyone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyloidosis ATTRV122I amyloidosis cardiomyopathy familial amyloid neuropathy wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY

Contacts and locations

Show contact details

Locations

Clinical Trial Site

Phoenix, Arizona, 85054, United States
Clinical Trial Site

Beverly Hills, California, 90211, United States
Clinical Trial Site

La Jolla, California, 92037, United States
Clinical Trial Site

Stanford, California, 94305, United States
Clinical Trial Site

Washington D.C., District of Columbia, 20010, United States
Clinical Trial Site

Chicago, Illinois, 60637, United States
Clinical Trial Site

Glenview, Illinois, 60026, United States
Clinical Trial Site

Indianapolis, Indiana, 46202, United States
Clinical Trial Site

Kansas City, Kansas, 66160, United States
Clinical Trial Site

Baltimore, Maryland, 21287, United States
Clinical Trial Site

Boston, Massachusetts, 02115, United States
Clinical Trial Site

Boston, Massachusetts, 02118, United States
Clinical Trial Site

Rochester, Minnesota, 55905, United States
Clinical Trial Site

St Louis, Missouri, 63110, United States
Clinical Trial Site

Omaha, Nebraska, 68198, United States
Clinical Trial Site

New York, New York, 10029, United States
Clinical Trial Site

New York, New York, 10032, United States
Clinical Trial Site

Durham, North Carolina, 27710, United States
Clinical Trial Site

Cleveland, Ohio, 44195, United States
Clinical Trial Site

Columbus, Ohio, 43214, United States
Clinical Trial Site

Philadelphia, Pennsylvania, 19104, United States
Clinical Trial Site

Nashville, Tennessee, 37232, United States
Clinical Trial Site

Dallas, Texas, 75246, United States
Clinical Trial Site

Salt Lake City, Utah, 84132, United States
Clinical Trial Site

Buenos Aires, C1093AAS, Argentina
Clinical Trial Site

Buenos Aires, C1199ABB, Argentina
Clinical Trial Site

Buenos Aires, C1428, Argentina
Clinical Trial Site

Córdoba, X5000KEH, Argentina
Clinical Trial Site

Rosario, S2000DEJ, Argentina
Clinical Trial Site

Rosario, S2000DSR, Argentina
Clinical Trial Site

Rosario, S2000PBJ, Argentina
Clinical Trial Site

Vienna, 1090, Austria
Clinical Trial Site

Vienna, 1210, Austria
Clinical Trial Site

Aalst, 9300, Belgium
Clinical Trial Site

Anderlecht, 1070, Belgium
Clinical Trial Site

Dendermonde, 9200, Belgium
Clinical Trial Site

Ghent, 9000, Belgium
Clinical Trial Site

Hasselt, 3500, Belgium
Clinical Trial Site

Leuven, 3000, Belgium
Clinical Trial Site

Liège, 4000, Belgium
Clinical Trial Site

Roeselare, 8800, Belgium
Clinical Trial Site

Ribeirão Preto, 14026-900, Brazil
Clinical Trial Site

Ribeirão Preto, 14051-140, Brazil
Clinical Trial Site

Rio de Janeiro, 22280-020, Brazil
Clinical Trial Site

São Paulo, 04012-180, Brazil
Clinical Trial Site

São Paulo, 05403-000, Brazil
Clinical Trial Site

Prague, 120 00, Czechia
Clinical Trial Site

Prague, 128 21, Czechia
Clinical Trial Site

Prague, 140 21, Czechia
Clinical Trial Site

Aarhus N, 8200, Denmark
Clinical Trial Site

København Ø, 2100, Denmark
Clinical Trial Site

Odense C, 5000, Denmark
Clinical Trial Site

Créteil, 94000, France
Clinical Trial Site

Marseille, 13005, France
Clinical Trial Site

Paris, 75018, France
Clinical Trial Site

Rennes, 35000, France
Clinical Trial Site

Toulouse, 31059, France
Clinical Trial Site

Bologna, 40138, Italy
Clinical Trial Site

Florence, 50134, Italy
Clinical Trial Site

Pavia, 27100, Italy
Clinical Trial Site

Groningen, 9713 GZ, Netherlands
Clinical Trial Site

Maastricht, 6229 HX, Netherlands
Clinical Trial Site

Utrecht, 3584 CX, Netherlands
Clinical Trial Site

Oslo, 372, Norway
Clinical Trial Site

Creixomil, 4835-044, Portugal
Clinical Trial Site

Lisbon, 1649-035, Portugal
Clinical Trial Site

Porto, 4099-001, Portugal
Clinical Trial Site

Viseu, 3504-509, Portugal
Clinical Trial Site

Seoul, 03080, South Korea
Clinical Trial Site

Seoul, 03722, South Korea
Clinical Trial Site

Seoul, 06351, South Korea
Clinical Trial Site

Barcelona, 08035, Spain
Clinical Trial Site

Bilbao, 48013, Spain
Clinical Trial Site

L'Hospitalet de Llobregat, 8907, Spain
Clinical Trial Site

Madrid, 28222, Spain
Clinical Trial Site

Málaga, 29010, Spain
Clinical Trial Site

Gothenburg, 413 45, Sweden
Clinical Trial Site

Solna, 171 76, Sweden
Clinical Trial Site

Umeå, 907 37, Sweden
Clinical Trial Site

Taipei, 112, Taiwan
Clinical Trial Site

Bellshill, ML4 3NJ, United Kingdom
Clinical Trial Site

Birmingham, B15 2SQ, United Kingdom
Clinical Trial Site

Cardiff, CF15 9SS, United Kingdom
Clinical Trial Site

Hexham, NE46 1QJ, United Kingdom
Clinical Trial Site

London, NW3 2QG, United Kingdom
Clinical Trial Site

London, SE1 1YR, United Kingdom
Clinical Trial Site

Manchester, M15 6SE, United Kingdom